Urologic cancer registry study
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This registry study collects information from people with different types of advanced or high-risk urologic cancers. It helps doctors learn more about how these cancers are treated in real life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have one of the following: advanced kidney cancer (aRCC), advanced bladder cancer (aUBC), muscle-invasive bladder cancer (MIBC), or high-risk muscle-invasive urothelial cancer (MIUC).
- For aRCC or aUBC: You are about to start your first systemic treatment (like chemotherapy or targeted therapy) for this cancer.
- For high-risk MIUC: You had radical surgery (removal of the bladder or kidney) between October 2021 and October 2024 and your cancer was at high risk of coming back.
- For MIBC: You were diagnosed with muscle-invasive bladder cancer and have not yet had treatment that is only for comfort (palliative).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at patients with kidney cancer that hasn't spread and is considered high-risk. It uses a registry to learn more about these patients to improve future care.
This trial is for people diagnosed with a rare type of cancer in the upper urinary tract (UTUC). Researchers hope to learn more about this condition and find better ways to treat it.
This trial tests whether giving radiation therapy before surgery can help people with high-risk upper tract urothelial cancer (UTUC). The goal is to improve treatment outcomes for patients who are planning to have their cancer removed.
This trial is testing whether adding immunotherapy and radiation after surgery can improve outcomes for people with advanced upper tract urothelial cancer (UTUC) who cannot have chemotherapy. It compares the combination to surgery alone.
This study is collecting blood, urine, and tissue samples from people with high-risk non-muscle invasive bladder cancer to help develop better tests for tracking the disease. By participating, you might help improve future monitoring and treatment decisions.
This study checks tumor DNA found in blood and urine to see who is at higher risk of the cancer coming back after surgery. It may help doctors identify “minimal residual disease,” meaning tiny amounts of cancer that can remain after treatment.
Hear when a new Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.